-
A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.
Factor VIII (antihemophilic factor) is a high molecular weight plasma glycoprotein that participates in the blood clotting cascade. The recent cloning and sequence analysis of the cDNA encoding human factor VIII revealed an obvious domain structure for the protein, which can be represented as A1-A2-B-A3-C1-C2. We now report the DNA sequence analysis of porcine exons encoding the entire B domain and part of the A2 and A3 domains. We found an unusually high degree of porcine-human amino acid sequence divergence in the B region compared with the limited sequence available for other regions of the porcine factor VIII molecule. In addition to sequence divergence, there are numerous gaps in the porcine B domain totalling over 200 amino acids. Recombinant DNA techniques were used to effect the removal of large segments of DNA encoding the B domain from the full-length human factor VIII cDNA. These constructs directed the synthesis of biologically active factor VIII when introduced into mammalian cells despite the deletion of up to 38% of the factor VIII molecule.
PMID: 3016730 [PubMed - indexed for MEDLINE]
PMCID: PMC386412
-
Cited by 21 PubMed Central articles
-
ReviewGene therapy for haemophilia.
Murphy SL, High KA.
Br J Haematol. 2008 Mar; 140(5):479-87.
[Br J Haematol. 2008]
-
O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.
Miclea RD, Purohit VS, Balu-Iyer SV.
AAPS J. 2007 Jun 29; 9(2):E251-9. Epub 2007 Jun 29.
[AAPS J. 2007]
-
The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.
Chen L, Zhu F, Li J, Lu H, Jiang H, Sarkar R, Arruda VR, Wang J, Zhao J, Pierce GF, et al.
Mol Ther. 2007 Oct; 15(10):1856-62. Epub 2007 Jul 24.
[Mol Ther. 2007]
- » See all...